

# **Cervix Cancer A GCIIG Perspective**

**Keiichi Fujiwara, MD, PhD**

**Saitama Medical University International Medical Center,  
Japan**


**GCIIG Chair**




## Cervical Cancer

- Second most common cancer among women worldwide.
- Second most common cause of cancer-related mortality in women globally.
- Human papillomavirus (HPV) infections are the cause of nearly all cervical cancers.
- Preventable through screening and vaccination

# A Prototype: Estimated Cervical Cancer Mortality Worldwide




**Estimated Age-Standardised rates per 100,000**



✓ Globocan 2012 - WHO

# Gynecologic Cancer InterGroup Cervix Cancer Research Network



GLOBOCAN 2018, WHO

Cervix Cancer Education Symposium, January 2019, South Africa

## Cervical Cancer

- Second most common cancer among women worldwide.
- Second most common cause of cancer-related mortality in women globally.
- Human papillomavirus (HPV) infections are the cause of nearly all cervical cancers.
- Preventable through screening and vaccination
- If not prevented
  - Early Stage Disease: Surgery
  - Locally Advanced Disease: Chemoradiation
  - Metastatic Disease: Chemotherapy

## Research Questions for Cervical Cancer

- For Early Stage Disease
  - ? Less invasive surgery improves QOL without compromise survival
- For Locally Advanced Disease
  - ? Addition of Adjuvant Chemotherapy to CRT improves survival
  - ? Combination of Immunotherapy improves survival
- For Metastatic Disease
  - ? Combination of antiangiogenics improves survival
  - ? Combination of Immunotherapy improves survival




## To Obtain Answers to the Research Questions for Cervical Cancer

- Clinical Trials is inevitable!



# Progress in Survival in Advanced and Recurrent Cervical Cancer





## To Obtain Answers to the Research Questions for Cervical Cancer

- Clinical Trials is inevitable with
    - Multidisciplinary
    - Multicenter
    - International
- Collaboration

GCIG

# Gynecologic Cancer InterGroup Cervix Cancer Research Network

<https://gciggroup.com/>



Cervix Cancer Education Symposium, January 2019, South Africa



- Mission Statement:
  - The Gynecological Cancer InterGroup aims to promote and facilitate high quality clinical trials in order to improve outcomes for women with gynecological cancer.

- Vision Statement:
  - Improving quality and duration of life for women with gynecologic cancers will be accomplished through a focused common purpose, shared expertise, and mutual respect among members, and with recognition and accommodation of cultural, geographic, and clinical diversities amongst and between members and patients.




# GCIG

## Current Situation


- Currently 32 groups are GCIG members.
  - 16 Europe
  - 7 US and Canada
  - 6 ASIA
  - 1 Australia/New Zealand
  - 2 Latin America
  - 0 Africa



Countries represented in the GCIG 2015



# Countries represented in the GCIIG future?



## Summary

- Incidence of cervical cancer is extremely higher in developing countries.
- Therefore, it is strategically important to get the involvement of those countries for the development of new therapies.
- GCIg is now playing an major role to conduct clinical trials for cervical cancer in those countries in collaboration with CCRN.

# Gynecologic Cancer InterGroup Cervix Cancer Research Network



Cervix Cancer Education Symposium, January 2019, South Africa